Features
Get A Demo
Plans
Sign Up
Login
All Federal Grant Programs
Allergy and Infectious Diseases Research
Posted
8/17/18
Assistance Listing Number
93.855
Overview
Grant Opportunities
4
Grant Awards
1
Federal Agency
National Institutes of Health
Applicant Types
Not listed
Beneficiary Types
Not listed
Additional Information
Not listed
Popular Federal Grant Opportunities
Not listed
Popular Federal Grant Awards
Not listed
Name
Description
Awardee
Assistance Type
Dollars Obligated
(Click to sort descending)
Award Date
(Click to sort descending)
Updated At
(Click to sort descending)
P01AI178375
MULTI-OMIC UNDERSTANDING OF THE TRANSFORMED HOST T-CELL RESPONSE TO HIV FOLLOWING THERAPEUTIC VACCINATION - THERAPEUTIC HIV VACCINES CONFRONT AN IMMUNE SYSTEM WHOSE ANTI-PATHOGEN RESPONSES ARE ESTABLISHED AND HAVE USUALLY BEEN EVOLVING FOR YEARS. T-CELL RESPONSES TO IMMUNODOMINANT EPITOPES HAVE BEEN GENERATED AND MAY HAVE BEEN MAINTAINED-OR COULD HAVE FORCED VIRAL ESCAPE AND EVENTUAL EXPANSION OF T CELLS WITH ALTERNATIVE, ORIGINALLY SUB-DOMINANT SPECIFICITIES. MANY HIV-SPECIFIC T CELLS HAVE LOW PROLIFERATIVE CAPACITY, RENDERING THEM INCAPABLE OF A ROBUST RESPONSE WHEN ANTIRETROVIRAL TREATMENT IS STOPPED. FURTHERMORE, THE ESTABLISHED T-CELL REPERTOIRE FAILED TO CONTROL ACUTE INFECTION, SO EXPANSION OF PRE-EXISTING T CELLS WITH THEIR ATTENDANT FUNCTIONAL DEFICIENCIES IS UNLIKELY TO BE THERAPEUTICALLY EFFECTIVE. THE PRIMARY GOAL OF THERAPEUTIC VACCINATION MUST INSTEAD BE EXPANSION OF NEW T-CELL CLONES WITH SUPERIOR FUNCTION, AND/OR THE RESTORATION OF FUNCTION TO PRE-EXISTING MEMORY CELLS. WE SUGGEST THAT ONLY SUCH QUALITATIVE IMPROVEMENTS CAN PROVIDE THE HOST WITH NEW CAPACITY FOR CONTROL OVER THE VIRUS. A CENTRAL OBJECTIVE OF OUR PROGRAM IS TO UNDERSTAND THE EXTENT TO WHICH PRE-EXISTING HOST IMMUNE AND METABOLIC FEATURES CONSTRAIN THE QUALITY OF T-CELL RESPONSES TO THERAPEUTIC VACCINATION. WHICH IMMUNOMETABOLIC CONDITIONS PREDICT AND PERHAPS FOSTER QUALITATIVELY SUPERIOR RESPONSES? WHAT FRACTION OF THE T-CELL RESPONSE TO VACCINATION IS REPRESENTED BY NEW AND PREVIOUSLY UNDETECTED CLONOTYPES, AND HOW DO THE FUNCTIONAL CAPACITIES AND DIFFERENTIATION OF THE NEW CLONOTYPES DIFFER FROM PRE-EXISTING ONES? A SECOND MAJOR OBJECTIVE IS TO EVALUATE THE RELATIVE ABILITY OF DIFFERENT VACCINE REGIMENS AND METABOLIC INTERVENTIONS TO EXPAND NEW HIV/SIV-SPECIFIC T CELLS WITH STEM-LIKE QUALITIES. WE AND OTHERS HAVE SHOWN THAT HIV-SPECIFIC T CELLS IN NATURAL HIV CONTROLLERS EXPRESS HIGH LEVELS OF THE MEMORY-PROMOTING TRANSCRIPTION FACTOR, TCF-1, RETAIN PROLIFERATIVE CAPACITY, AND EXHIBIT METABOLIC PLASTICITY. WE HYPOTHESIZE THAT VACCINE- INDUCED CELLS WITH STEM-LIKE PROPERTIES OFTEN DERIVE FROM NAÏVE T-CELL CLONOTYPES NOT PREVIOUSLY EXPANDED OR CHRONICALLY EXPOSED TO ANTIGEN, AND THAT DIFFERENT VACCINE REGIMENS DIFFER IN THEIR ABILITY TO RECRUIT SUCH CELLS. A THIRD AND CENTRAL OBJECTIVE OF OUR EFFORT IS TO LEARN HOW PEPTIDE SPECIFICITY, STEMNESS, AND METABOLIC CAPACITIES OF T CELLS RESPONDING TO VACCINATION ARE RELATED TO CONTROL OVER VIREMIA DURING ATI. A LARGE LITERATURE SUPPORTS OUR PREMISE THAT HIGH T-CELL QUALITY IS REQUIRED FOR CONTROL OVER VIREMIA, AND MORE SPECIFICALLY THAT T CELL MEMORY, OR "STEMNESS", FEATURES ARE ASSOCIATED WITH EFFECTIVE HOST RESPONSES. HOWEVER, THESE CONNECTIONS REMAIN RELATIVELY UNEXPLORED IN THE CONTEXT OF THERAPEUTIC VACCINATION, IN PART DUE TO SCARCITY OF LARGE THERAPEUTIC-VACCINE STUDIES THAT HAVE YIELDED AN APPRECIABLE EFFICACY SIGNAL. WE WILL USE SAMPLES FROM HUMAN AND NON-HUMAN PRIMATE THERAPEUTIC-VACCINE STUDIES THAT HAVE SHOWN EVIDENCE FOR T CELL-MEDIATED VIROLOGIC SUPPRESSION TO UNDERSTAND IF THE T-CELL FEATURES PREVIOUSLY LINKED TO CONTROL OVER INFECTION ARE ALSO TYPICAL OF SUCCESSFUL IMMUNE RESPONSES TO THERAPEUTIC VACCINES.
University Of California, Davis
Project Grant
$6.9m
5/22/23
7/18/24
Name
Description
Solicitation Number
Federal Agency
Due Date
(Click to sort descending)
Posted Date
(Click to sort descending)
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.
PA-20-207
Department of Health and Human Services National Institutes of Health
2/10/21
5/8/20
Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
This federal grant opportunity, titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)", is seeking exploratory and conceptual research projects focused on medical countermeasures, biodosimetry, and animal model development to diagnose, mitigate, and treat injuries arising from radiation exposure during a public health emergency. The grant is being offered by the Department of Health and Human Services National Institutes of Health under the Allergy and Infectious Diseases Research program (CFDA 93.855). Eligible applicant types include a wide range of organizations including non-profits, governments, and for-profit entities. The application deadline is November 1, 2024. The total estimated funding available and anticipated number of awards are not specified. Recent Federal Grant Awards under the Allergy and Infectious Diseases Research program have typically ranged from $35,000 to over $250,000 per year, with project periods of 2-5 years. Research is generally expected to be performed at the recipient institutions across the United States.
RFA-AI-24-041
Department of Health and Human Services National Institutes of Health
11/1/24
7/30/24
Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)
This Notice of Funding Opportunity (NOFO) seeks applications to fund a single Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS), a 7-year epidemiological study of approximately 5,500 middle-aged and older people living with and without HIV across the United States. The funding opportunity is issued by the Department of Health and Human Services National Institutes of Health and is limited to institutions previously funded under RFA-HL-19-007. The study will utilize a populomics approach to examine health determinants across multiple scales of influence, from molecular to sociopolitical levels. The application deadline is May 2, 2025. The NOFO does not specify an exact award value, but previous grants under the associated federal programs have ranged from approximately $35,000 to over $2 million, with typical project periods spanning 2-5 years. The research is expected to be conducted at the recipient organization's facilities across the United States.
RFA-HL-26-010
Department of Health and Human Services National Institutes of Health
5/2/25
1/16/25
Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
Paragraph 1: This Federal Grant Opportunity, Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional), is seeking applications from single institutions or consortia to participate in a research program focused on understanding the mechanisms underlying the onset and progression of diseases such as asthma, rhinitis, chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The funding will be provided through the U19 cooperative agreement mechanism by the Department of Health and Human Services' National Institutes of Health. The goal is to conduct integrated clinical and translational research to improve the understanding of disease pathogenesis and provide a rational foundation for new, effective treatments and prevention strategies. Applications are open to a wide range of eligible entities including nonprofits, businesses, tribal organizations, and government entities. The deadline for submitting proposals is June 13, 2025. Paragraph 2: The funding for this opportunity is part of the broader Allergy and Infectious Diseases Research program (CFDA 93.855), which typically supports awards ranging from $35,000 to $250,000 annually with project periods spanning 2-5 years. The research is expected to be conducted at the recipient facilities across the United States.
RFA-AI-24-079
Department of Health and Human Services National Institutes of Health
6/13/25
1/16/25